Table 1.
Ramucirumab in non-small-cell lung cancer
| Study | Study design | Lines of treatment | Chemotherapy | Sample size (n) | ORR (%) | Md PFS (months) | Md OS (months) |
|---|---|---|---|---|---|---|---|
| Camidge et al22 | Phase II Single-arm Open-label |
Treatment-naïve | Carboplatin-paclitaxel plus ramucirumab | 40 | 55 | 7.85 | 16.85 |
| Doebele et al23 | Phase II Randomized Open-label |
Treatment-naïve | Carboplatin or cisplatin-pemetrexed with pemetrexed-ramucirumab vs pemetrexed alone | 140 | 49.3 vs 38 p=0.17 |
7.2 vs 5.6 p=0.13 |
13.9 vs 10.4 p=0.89 |
| Garon et al24 | Phase III Double-blind |
Second line | Docetaxel plus ramucirumab vs docetaxel plus placebo | 1,253 | 23 vs 14 | 4.5 vs 3.0 | 10.5 vs 9.1 |
| Shiono et al28 | Retrospective study | Following disease progression after nivolumab treatment | Ramucirumab plus docetaxel | 20 | 60 | 5.6 | 11.4 |
Abbreviations: ORR, objective response rate; Md PFS, median progression-free survival; Md OS, median overall survival.